Company Overview

Development Stage

About the Company

[Summary] To become an enterprise with value of existence, serving human health

In 1996, Eisai (China) Pharmaceutical Co., Ltd., a wholly foreign-owned pharmaceutical enterprise invested by Eisai Co., Ltd., a world-renowned pharmaceutical group from Japan, settled in the park. The headquarters of Eisai was founded in 1941, with overseas companies distributed across Europe, America, and Asia, and has more than 10 innovative drugs, covering five major therapeutic areas including the central nervous system, digestive system, endocrine, orthopedics, and oncology.

As part of Eisai's global manufacturing system, Eisai Suzhou Factory is located in Suzhou Industrial Park, registered in March 1996, and successfully relocated from Baiyu Road to the new factory on Xingpu Road in 2018, covering an area of 130,000 square meters, with local production capabilities for solid dosage forms, injections, and other formulations. In the future, in addition to meeting the clinical medication needs of Chinese patients, the Suzhou factory will also provide high-quality products to other Asian countries and regions to meet patient needs. The Suzhou factory will continue to introduce anti-tumor drugs, develop new formulations, and innovate product processes, seeking sustained profitability.

Eisai (China) adheres to the corporate purpose of human health care (hhc), with Compliance as the code of conduct and GMP as the quality standard. Relying on high-quality, effective products and stable supply, it focuses deeply on the pharmaceutical field. Facing the fiercely competitive pharmaceutical market, it has been in China for over two decades, striving diligently and continuously innovating. For many years, it has ranked among the top pharmaceutical companies in China, achieving double-digit performance growth annually and demonstrating a strong sense of social responsibility, winning praise and respect from peers and all sectors of society.

While developing steadily and sustainably, Eisai also places great emphasis on humanistic care and employee development, offering competitive compensation and benefits, employee training and development systems, and a harmonious and healthy working environment. It has also been awarded the title of Top Employer in Greater Suzhou for four consecutive years from 2017 to 2020, China's Outstanding Employer for 2020-2021, Suzhou Industrial Park 5A-level Labor Security Credit Unit, the park's enterprise with the strongest sense of social responsibility, one of the top 20 tax contribution enterprises, and various social welfare awards, as well as the Top Ten Enterprise for Headquarters Economy.

Corporate values: Innovation, Pursuit of Excellence, Ownership, Integrity, Teamwork

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Eisai China Recruitment Overview / Current Status (59 open positions)

Manage
Note: How fast is hiring at Eisai (China) Pharmaceutical Co., Ltd. growing? Eisai China2025: 111 openings (up 19%), 2024: 93 openings (down 31%), 2023: 135 openings (up 2%), 2022: 133 openings (up 51%), 2021: 88 openings. A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Eisai China Master's Degree Job Demand Analysis

(More)
N/A
Growth Rate
Eisai China Master's Hiring by Year: 2025 — 3 fewer jobs than 2024
* Hiring was generally low during 2020-2022 due to the pandemic
How fast is master's hiring at Eisai (China) Pharmaceutical Co., Ltd. growing? Eisai ChinaMaster's recruitment over the years: 2025: 3 openings (up 19%), 2024: 6 openings (down 31%), 2023: 21 openings (up 2%), 2022: 8 openings (up 51%), 2021: 4 openings.

Eisai China — What Are the Salaries Like? (112 records)

Manage
salary range: 2K - 30K, 76.8% of roles pay ¥8-15K
Note: salary statistics are based on 112 salary records from the past year and depend on the job sample. For reference only.
How is the salary at Eisai (China) Pharmaceutical Co., Ltd.?Eisai China76.8% of positions earn 8-15K, Fresh graduate salary: ¥3.8K。销售类 average salary ¥13.4K。 Note: Based on analysis of job postings, does not represent current on-the-job positions; system stability may affect objectivity. For reference only.Data inaccurate? Let us know

Salaries for hot jobs of Eisai China

(More)
Are salaries high at Eisai (China) Pharmaceutical Co., Ltd.? We provide: 医药代表,销售,地区经理,实习生,临床,仓库,值班工程师,库管,日语,翻译,qa,大区经理,推广,操作工,新媒体,设备工,设备技术,运营,采购,高级专员. Click to view detailed salary analysis by job.

Eisai China honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

Eisai China Related Industry Tags

Job Category

  • 销售类
    86% of total 86%
  • 经营管理类
    5.3% of total 5.3%
  • 在校学生类
    4.4% of total 4.4%
  • 医疗卫生/美容保健类
    3.5% of total 3.5%

Education

  • 大专
    67.5% of total 67.5%
  • 本科
    28.1% of total 28.1%
  • 高中
    3.5% of total 3.5%
  • 不限
    0.9% of total 0.9%

Experience

  • 1-3年
    69.3% of total 69.3%
  • 不限
    17.5% of total 17.5%
  • 3-5年
    7% of total 7%
  • 5-10年
    5.3% of total 5.3%
View Detailed Analysis

What does Eisai (China) Pharmaceutical Co., Ltd. require? Who is Eisai China hiring? Eisai China recruitment: 销售类占比最多占86%,其次是经营管理类占5.3%. What education can get in at Eisai China? 大专占比最多占67.5%,其次是本科占28.1%. Work experience required at Eisai China? 1-3年占比最多占69.3%,其次是不限占17.5%. Where are the job locations at Eisai China? 苏州占比最多占11.4%,其次是上海占7.9%. Based on job postings from the past year, for reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 7,854万(美元)
Legal Representative: 冯艳辉
Date Established:
Credit Code: 91320594608205450R
Registered Address: 苏州工业园区兴浦路168号

Partners & Suppliers

合恩医药采购卫材的神经系统、消化系统药品。 Source
合作客户 化学药
国药股份采购卫材的神经病学及肿瘤药物用于分销 Source
合作客户 化学药品(跨国原研药企)
卫材与柳药集团合作,在广西推广神经科产品。 Source
合作客户 化学药品制造
微芯生物与日本卫材株式会社达成协议,授予西达本胺在日本及部分亚洲国家(不含中国)的开发和商业化权益,卫材(中国)药业有限公司为其在华运营实体,合作包含首付款及里程碑付款 Source
供应商 海外授权客户
神经科药物合作,大参林销售卫材的弥可保、安理申等 Source
合作客户 化学药/处方药企业

People who follow Eisai China also follow

Eisai China Competitors (Similar Companies)

“To develop high-quality biologics that are accessible and affordable f”
制药/药业 心血管药 神经系统疾病药物 药物研发
“A renowned enterprise in China's liver disease and anti-tumor fields”
中间体 生产 原料药 中间体生产
“Research, development, and production of anti-tumor and surgical medic”
“To make people live longer, healthier, and more vital lives”
“Health for Humanity, Creating a Better Future Together”
“Make it easy to do business anywhere”
“A technology-driven international pharmaceutical enterprise”
“Comprehensive manufacturer and supplier of imaging, information, and d”
“Metal structural parts, functional parts, and appearance parts”
制药/药业 生物制药 原料药 心血管药
“Continuous innovation, safeguarding health”
“Accelerating global biologic drug R&D processes, reducing R&D costs, a”
制药/药业 药物研发 新药研发 CRO

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates